ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,433.76
0.63%
Dow Jones
39,512.84
0.32%
Gold vs US Dollar
2,360.48
0.00%
Brent Oil
82.585
0.00%
Bitcoin
61,504.56
1.16%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Syndax Pharmaceuticals Inc (SNDX)

  7. Syndax Pharmaceuticals Inc (SNDX) News

Syndax Pharmaceuticals (SNDX)

Syndax Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SNDX
DateTimeSourceHeadlineSymbolCompany
09/05/202412:00PR Newswire (US)Syndax Announces Participation at the Bank of America Securities 2024 Health Care ConferenceNASDAQ:SNDXSyndax Pharmaceuticals Inc
08/05/202412:06PR Newswire (US)Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business UpdateNASDAQ:SNDXSyndax Pharmaceuticals Inc
08/05/202412:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNDXSyndax Pharmaceuticals Inc
08/05/202412:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNDXSyndax Pharmaceuticals Inc
03/05/202421:05PR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
01/05/202412:00PR Newswire (US)Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024NASDAQ:SNDXSyndax Pharmaceuticals Inc
10/04/202421:05PR Newswire (US)Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology ForumNASDAQ:SNDXSyndax Pharmaceuticals Inc
08/04/202412:00PR Newswire (US)Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary SessionNASDAQ:SNDXSyndax Pharmaceuticals Inc
05/04/202421:05PR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
28/03/202411:00PR Newswire (US)Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid LeukemiaNASDAQ:SNDXSyndax Pharmaceuticals Inc
26/03/202420:05PR Newswire (US)Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute LeukemiaNASDAQ:SNDXSyndax Pharmaceuticals Inc
18/03/202411:00PR Newswire (US)Syndax Announces Appointment of Steven Closter as Chief Commercial OfficerNASDAQ:SNDXSyndax Pharmaceuticals Inc
01/03/202421:05PR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
27/02/202422:28Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:SNDXSyndax Pharmaceuticals Inc
27/02/202422:21Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SNDXSyndax Pharmaceuticals Inc
27/02/202421:05PR Newswire (US)Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:SNDXSyndax Pharmaceuticals Inc
27/02/202421:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNDXSyndax Pharmaceuticals Inc
26/02/202412:00PR Newswire (US)Syndax Announces Participation at Two Upcoming Investor ConferencesNASDAQ:SNDXSyndax Pharmaceuticals Inc
20/02/202421:05PR Newswire (US)Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024NASDAQ:SNDXSyndax Pharmaceuticals Inc
14/02/202417:50Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SNDXSyndax Pharmaceuticals Inc
14/02/202412:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SNDXSyndax Pharmaceuticals Inc
14/02/202402:44Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SNDXSyndax Pharmaceuticals Inc
09/02/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNDXSyndax Pharmaceuticals Inc
09/02/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNDXSyndax Pharmaceuticals Inc
09/02/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNDXSyndax Pharmaceuticals Inc
09/02/202421:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNDXSyndax Pharmaceuticals Inc
09/02/202421:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNDXSyndax Pharmaceuticals Inc
09/02/202421:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNDXSyndax Pharmaceuticals Inc
09/02/202421:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNDXSyndax Pharmaceuticals Inc
02/02/202421:05PR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SNDX

Your Recent History

AMEX
BNC
Bns
ASX
CLB
Candy Club
COIN
TURBOEUR
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved